fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Analyses published in NEJM of a third booster shot of the Comirnaty messenger RNA vaccine from Pfizer

Written by | 19 Sep 2021

Publication of two separate analyses in The New England Journal of Medicine comes before a meeting of FDA advisers to discuss Pfizer’s application for authorization of a third… read more.

Adjuvant anti-inflammatory baricitinib reduces mortality in COVID-19

Written by | 18 Sep 2021

Addition of baricitinib to standard of care (including dexamethasone and remdesivir) was associated with reduced mortality among hospitalized adults with COVID-19, researchers reported on Sept. 1, 2021 in… read more.

Moderna announces submission of initial data to the FDA for mRNA-1273 at the 50 µg dose level

Written by | 7 Sep 2021

Moderna, Inc., announced it has initiated its submission to the FDA for the evaluation of a booster dose of the Moderna COVID-19 vaccine (mRNA-1273) at the 50 µg… read more.

EU approval boosts COVID vaccine manufacturing capacity

Written by | 5 Sep 2021

The European Medicines Agency (EMA) has approved additional manufacturing capacity for the Pfizer/BioNTech COVID-19 vaccine in France – increasing production by 51 million doses by the end of… read more.

Pfizer and BioNTech announce submission of initial data to FDA to support booster dose of COVID-19 Vaccine

Written by | 31 Aug 2021

Pfizer Inc. and BioNTech SE announced that they have submitted Phase 1 data to the FDA to support the evaluation of a third, or booster, dose of the… read more.

Ronapreve, the first monoclonal antibody treatment for COVID-19 approved for use in the UK – Regeneron + Roche

Written by | 26 Aug 2021

Following on from a thorough review of the evidence carried out by the MHRA, and recommendation by the Commission on Human Medicines (CHM), the government’s independent expert scientific… read more.

Anticoagulation therapy improves outcomes in moderately ill COVID-19 patients

Written by | 24 Aug 2021

Moderately ill patients hospitalized with COVID-19 have achieved a better rate of respiratory organ support-free days and survival if treated with therapeutic-dose anticoagulation, researchers reported on August 20,2021… read more.

Vaxzevria and mRNA COVID-19 vaccines showed similar and favourable safety profiles in a population-based cohort study of over a million people – AstraZeneca

Written by | 14 Aug 2021

In a large real-world study, data published as a pre-print on The Lancet server from over one million individuals assessed the incidence rates of blood clotting disorders of… read more.

Applying the results of the ivermectin meta-analysis

Written by | 12 Aug 2021

The results of the ivermectin meta-analysis could have important implications for health policy. Dr Edmund Fordham, one of the co-authors of the review, describes how the findings could… read more.

Critical questions on the ivermectin meta-analysis

Written by | 12 Aug 2021

The methodological approach to the ivermectin meta-analysis provides further reassurance of the robustness of the findings. Mr Andrew Bryant and Dr Edmund Fordham describe some of the critical… read more.

Putting the findings of the ivermectin meta-analysis into perspective

Written by | 12 Aug 2021

The Bryant-Lawrie meta-analysis included only randomised controlled trials (RCTs) but evidence from observational trials and real world experience sheds further light on the effectiveness of ivermectin, according to… read more.

Key findings from the ivermectin meta-analysis

Written by | 12 Aug 2021

June 2021 saw the publication of the systematic review and meta-analysis of randomised controlled trials of ivermectin for treatment and prophylaxis of covid-19 undertaken by Dr Tess Lawrie’s… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.